



FOR IMMEDIATE RELEASE:

EyeGate Pharma Appoints Amy Cohen As Vice President, Clinical Operations

Company Prepares for Clinical Trials of EyeGate II Delivering Lead Compound, EGP-437

Waltham, MA, – June 16, 2008 – EyeGate Pharma, a privately held, specialty pharmaceutical company using iontophoresis technology to safely and non-invasively deliver therapeutics into the front and back of the eye to treat serious ocular diseases, today announced the appointment of Ms. Amy Cohen as Vice President, Clinical Operations.

Stephen From, President and Chief Executive Officer of EyeGate, commented on the appointment, "Amy brings a great deal of clinical operations experience to EyeGate. She has been centrally involved in bringing early clinical programs through to late stage development. Amy will play a key role managing clinical development of EyeGate's lead clinical compound, EGP-437, delivered via the EyeGate® II Ocular Delivery System. Our lead program, in anterior uveitis, is scheduled to enter into Phase I/II clinical development in the near future, followed by dry eye later in 2008."

Recently, EyeGate initiated a voluntary Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Drug Delivery System in up to 95 healthy adult volunteers. This GCP Phase I study was designed to establish the maximum tolerated current that can be employed with the EyeGate® II. This information will help shape future clinical trials and support future regulatory requirements.

Amy Cohen brings more than 20 years of clinical development and healthcare experience to EyeGate. Most recently she was Director, Clinical Operations at Javelin Pharmaceuticals. At Javelin, she provided overall clinical operations management and planning for Phase I through Phase 3 clinical studies for two of the three clinical candidates for acute pain (Dyloject™ and Rylomine™). Previously, Ms. Cohen was Program Manager, Clinical Trials/Medical Affairs at Becton, Dickinson and Company, where she oversaw all clinical trials within the ophthalmic surgery program. She has also held clinical operations leadership positions at Boston Scientific and Biogen Idec.

She holds a M.S. in Health Policy & Management from Harvard University School of Public Health and B.A. from Wellesley College.

-more-

About EyeGate Pharma

EyeGate Pharma has recently initiated a Phase I clinical study designed to assess the safety and tolerability of the non-invasive EyeGate® II Ocular Drug Delivery System and plans to initiate Phase 2 clinical trials in 2008 in uveitis and dry eye. EyeGate was founded in 1999 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (white membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was developed to safely deliver a wide range of therapeutics to both the anterior (front) and posterior (back) chambers of the eye. For more information please visit www.eyegatepharma.com.

#

IR/PR Contact:

Bryan Murphy or Tim Allison
LaVoie Group
978-745-4200 X105 or X102
bmurphy@lavoiegroup.com or
tallison@lavoiegroup.com